Pharmaceuticals Africa

Africa Influenza Antivirals Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Africa Influenza Antivirals Market Industry Trends and Forecast to 2034: Segmented by (Drug, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $21.7 Mn Placeholder estimate
Estimate 2025 $22.9 Mn 1.8% of the global market
Projected 2034 $36.7 Mn 60.5% Adds $13.9 Mn over 9 forecast years
CAGR 2025–2034 5.4% Faster than 6% of 180 Pharmaceuticals markets here
Key players 5
  • Africa is 1.76% of the global market.
  • Among regions, the largest is North America at $633.6 Mn.
  • Fastest growing: Africa (this report) at 5.4% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$13.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Influenza Antivirals Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $21.7 Mn — —
2025 (base) $22.9 Mn +$1.2 Mn —
2026 (forecast) $24.1 Mn +$1.2 Mn +5.4%
2027 (forecast) $25.4 Mn +$1.3 Mn +11.1%
2028 (forecast) $26.8 Mn +$1.4 Mn +17.1%
2029 (forecast) $28.2 Mn +$1.4 Mn +23.4%
2030 (forecast) $29.8 Mn +$1.5 Mn +30.1%
2031 (forecast) $31.4 Mn +$1.6 Mn +37.1%
2032 (forecast) $33.1 Mn +$1.7 Mn +44.5%
2033 (forecast) $34.9 Mn +$1.8 Mn +52.3%
2034 (forecast) $36.7 Mn +$1.9 Mn +60.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Influenza Antivirals Market Analysis at a glance
Market size, 2025$22.9 Mn placeholder estimate
Forecast, 2034$36.7 Mn placeholder estimate
Growth (CAGR), 2025–20345.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, buyer and end user (see all)
Key playersRoche, Shionogi, GSK PLC, BioCryst Pharmaceuticals, Cipla Inc. (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Active clinical trials5 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Influenza Antivirals Market Analysis Executive Summary

Influenza antivirals treat flu and shorten illness if started early, and are stockpiled for pandemics.

Key segments of the influenza Antivirals market include drug (Oseltamivir, Baloxavir and Zanamivir) and buyer (Retail, Hospitals and Government Stockpiles).

Bar chart: Africa Influenza Antivirals market size, 2024–2034, placeholder estimates. $21.7 Mn in 2024, $22.9 Mn in 2025 and $36.7 Mn in 2034, 5.4% CAGR.
Africa Influenza Antivirals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Influenza Antivirals Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the influenza Antivirals market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the influenza Antivirals market.

Competitive Landscape for Influenza Antivirals Market in Africa

The influenza Antivirals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Influenza Antivirals Market in Africa

Influenza Antivirals in Africa: rules, payment and research

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3], SAHPRA (South Africa)⁠[4] and NAFDAC (Nigeria)⁠[5]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[6], the SHA (Kenya)⁠[7], planned National Health Insurance (South Africa)⁠[8] and out of pocket and the NHIA (Nigeria)⁠[9]. ClinicalTrials.gov lists 5 studies on Influenza Antivirals that are recruiting, active or about to start in Africa.⁠[10]

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] NAFDAC. Checked 19 Nov 2026.

[6] Universal Health Insurance Authority. Checked 14 Nov 2026.

[7] Social Health Authority. Checked 14 Nov 2026.

[8] National Department of Health. Checked 14 Nov 2026.

[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.

[10] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for influenza Antivirals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Influenza Antivirals right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Influenza Antivirals in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Influenza Antivirals market in Africa?
Placeholder estimate: about $22.9 Mn in 2025, rising to about $36.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Influenza Antivirals market in Africa growing?
Placeholder estimate: about 5.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Influenza Antivirals market report cover?
The report splits the market by drug (Oseltamivir, Baloxavir, Zanamivir, Peramivir), buyer (Retail, Hospitals, Government Stockpiles) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Influenza Antivirals market?
Key players include Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals and Cipla Inc..
What is driving the Influenza Antivirals market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
Who regulates Influenza Antivirals in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Influenza Antivirals are running in Africa?
5 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Influenza Antivirals?
PubMed lists 47 papers on Influenza Antivirals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on influenza and infectious diseases

See the topic